Cargando…

Rebound thymic hyperplasia after bone marrow transplantation in children with haemato-oncological diseases

AIM OF THE STUDY: To evaluate prevalence of rebound thymic hyperplasia (RTH) after bone marrow transplantation (BMT) in paediatric patients with haemato-oncological diseases. MATERIAL AND METHODS: Between February 2013 and December 2017, BMT was performed in 189 paediatric patients with haemato-onco...

Descripción completa

Detalles Bibliográficos
Autores principales: Arpaci, Taner, Karagun, Barbaros Sahin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6103237/
https://www.ncbi.nlm.nih.gov/pubmed/30150885
http://dx.doi.org/10.5114/wo.2018.75398
_version_ 1783349318834454528
author Arpaci, Taner
Karagun, Barbaros Sahin
author_facet Arpaci, Taner
Karagun, Barbaros Sahin
author_sort Arpaci, Taner
collection PubMed
description AIM OF THE STUDY: To evaluate prevalence of rebound thymic hyperplasia (RTH) after bone marrow transplantation (BMT) in paediatric patients with haemato-oncological diseases. MATERIAL AND METHODS: Between February 2013 and December 2017, BMT was performed in 189 paediatric patients with haemato-oncological diseases in our institution. Fifty-six patients who underwent at least two chest computed tomography (CT) exams performed before and after BMT were included in the study. Maximum transverse and anterior-posterior (AP) diameters and CT attenuation of the thymus were measured on axial images. Thymic enlargement was considered when both transverse and AP diameters increased. RTH was defined as the presence of thymic enlargement on CT after BMT relative to the CT taken before. RESULTS: Twenty of 56 patients (36%) demonstrated RTH (12 boys, 8 girls; age range = 4-18 years; median age = 9.8 years). In 20 patients with RTH, seven patients (35%) were diagnosed with ALL, five patients (25%) with thalassemia, two patients (10%) with AML, and one patient (5%) with various diseases. Mean follow-up period between pre-BMT CT and BMT was 46 days, which was 239 days between BMT and post-BMT CT. Mean thymic transverse and AP diameters were 9 mm and 16 mm, respectively, before BMT, which were 17 mm and 33 mm after BMT. Mean HU was 57 on contrast enhanced and 35 on unenhanced images before BMT, which were 59 and 36, respectively, after BMT. CONCLUSIONS: RTH is common finding after BMT in children with various haemato-oncological diseases and should be taken under consideration in paediatric patients after BMT.
format Online
Article
Text
id pubmed-6103237
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-61032372018-08-27 Rebound thymic hyperplasia after bone marrow transplantation in children with haemato-oncological diseases Arpaci, Taner Karagun, Barbaros Sahin Contemp Oncol (Pozn) Original Paper AIM OF THE STUDY: To evaluate prevalence of rebound thymic hyperplasia (RTH) after bone marrow transplantation (BMT) in paediatric patients with haemato-oncological diseases. MATERIAL AND METHODS: Between February 2013 and December 2017, BMT was performed in 189 paediatric patients with haemato-oncological diseases in our institution. Fifty-six patients who underwent at least two chest computed tomography (CT) exams performed before and after BMT were included in the study. Maximum transverse and anterior-posterior (AP) diameters and CT attenuation of the thymus were measured on axial images. Thymic enlargement was considered when both transverse and AP diameters increased. RTH was defined as the presence of thymic enlargement on CT after BMT relative to the CT taken before. RESULTS: Twenty of 56 patients (36%) demonstrated RTH (12 boys, 8 girls; age range = 4-18 years; median age = 9.8 years). In 20 patients with RTH, seven patients (35%) were diagnosed with ALL, five patients (25%) with thalassemia, two patients (10%) with AML, and one patient (5%) with various diseases. Mean follow-up period between pre-BMT CT and BMT was 46 days, which was 239 days between BMT and post-BMT CT. Mean thymic transverse and AP diameters were 9 mm and 16 mm, respectively, before BMT, which were 17 mm and 33 mm after BMT. Mean HU was 57 on contrast enhanced and 35 on unenhanced images before BMT, which were 59 and 36, respectively, after BMT. CONCLUSIONS: RTH is common finding after BMT in children with various haemato-oncological diseases and should be taken under consideration in paediatric patients after BMT. Termedia Publishing House 2018-04-23 2018 /pmc/articles/PMC6103237/ /pubmed/30150885 http://dx.doi.org/10.5114/wo.2018.75398 Text en Copyright: © 2018 Termedia Sp. z o. o. http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Original Paper
Arpaci, Taner
Karagun, Barbaros Sahin
Rebound thymic hyperplasia after bone marrow transplantation in children with haemato-oncological diseases
title Rebound thymic hyperplasia after bone marrow transplantation in children with haemato-oncological diseases
title_full Rebound thymic hyperplasia after bone marrow transplantation in children with haemato-oncological diseases
title_fullStr Rebound thymic hyperplasia after bone marrow transplantation in children with haemato-oncological diseases
title_full_unstemmed Rebound thymic hyperplasia after bone marrow transplantation in children with haemato-oncological diseases
title_short Rebound thymic hyperplasia after bone marrow transplantation in children with haemato-oncological diseases
title_sort rebound thymic hyperplasia after bone marrow transplantation in children with haemato-oncological diseases
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6103237/
https://www.ncbi.nlm.nih.gov/pubmed/30150885
http://dx.doi.org/10.5114/wo.2018.75398
work_keys_str_mv AT arpacitaner reboundthymichyperplasiaafterbonemarrowtransplantationinchildrenwithhaematooncologicaldiseases
AT karagunbarbarossahin reboundthymichyperplasiaafterbonemarrowtransplantationinchildrenwithhaematooncologicaldiseases